A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03466983 |
Recruitment Status :
Recruiting
First Posted : March 15, 2018
Last Update Posted : March 4, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
IBD | Drug: Iron Isomaltoside Drug: Ferric Carboxymaltose | Phase 4 |
Existing IV iron complexes differ in relation to the compounds capability to induce unintended hypophosphatemia to a degree defined as medical significant.
This trial is designed evaluate the effect of IV iron isomaltoside compared to IV ferric carboxymaltose on phosphate in subjects with IDA due to inflammatory bowel disease .
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | double-blinded |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease |
Actual Study Start Date : | May 23, 2018 |
Estimated Primary Completion Date : | April 30, 2020 |
Estimated Study Completion Date : | July 30, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Iron Isomaltoside
Iron Isomaltoside (Monofer) administered IV
|
Drug: Iron Isomaltoside
administered IV
Other Name: Monofer |
Active Comparator: Ferric Carboxymaltose
Ferric Carboxymaltose (Injectafer) administered IV
|
Drug: Ferric Carboxymaltose
administered IV
Other Name: Ferinject |
- Incidence of hypophosphatemia [ Time Frame: any time from baseline to day 35 ]s-phosphate < 2 mg/dL
- Incidence of hypophosphatemia [ Time Frame: any time from baseline to week 10 ]s-phosphate < 2 mg/dL
- Incidence of s-phosphate < 1.0 mg/dL [ Time Frame: any time from baseline to day 35 ]s-phosphate < 1.0 mg/dL
- Time with hypophosphatemia [ Time Frame: number of days any time from baseline to week 10 ]time with s-phosphate < 2.0 mg/dL

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria include:
- Men or women ≥ 18 years
- Subjects diagnosed with IBD
- Hb < 13 g/dL
- Body weight ≥ 50 kg
- S-ferritin <100 ng/mL
- eGFR ≥ 65 mL/min/1.73 m2
- S-phosphate > 2.5 mg/dL
- Oral iron preparations are ineffective or cannot be used or where there is a clinical need to de-liver iron rapidly
- Willingness to participate and signing the Informed Consent Form (ICF)
Exclusion Criteria include:
- Anaemia predominantly caused by factors other than IDA according to Investigator's judgment
- Hb ≥ 10 g/dL and body weight < 70 kg
- Hemochromatosis or other iron storage disorders
- Known hypersensitivity reaction to any component of iron isomaltoside or ferric carboxymaltose
- Previous serious hypersensitivity reactions to any IV iron compounds
- Treatment with IV iron within the last 30 days prior to screening
- Treatment with erythropoietin or erythropoietin-stimulation agents, red blood cell transfusion, radiotherapy, and/or chemotherapy within the last 30 days prior to screening
- Received an investigational drug within the last 30 days prior to screening
- Planned surgical procedure within the trial period
- hepatic enzymes > 3 times upper limit of normal
- Surgery under general anaesthesia within the last 30 days prior to screening
- Any non-viral infection within the last 30 days prior to screening
- Alcohol or drug abuse within the past 6 months
- Untreated hyperparathyroidism
- Kidney transplantation
- Conditions that interfere with the subject's ability to understand the requirements of the trial and/or presumable non-compliance
- Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements
- Pregnant or nursing women.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03466983
Contact: Pharmacosmos A/S Clinical and Non-clinical Research | +4559485959 | info@pharmacosmos.com |
Denmark | |
Pharmacosmos Investigational Site | Recruiting |
Silkeborg, Denmark, 8600 |
Responsible Party: | Pharmacosmos A/S |
ClinicalTrials.gov Identifier: | NCT03466983 |
Other Study ID Numbers: |
P-Monofer-IBD-03 |
First Posted: | March 15, 2018 Key Record Dates |
Last Update Posted: | March 4, 2020 |
Last Verified: | October 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Inflammatory Bowel Diseases Anemia, Iron-Deficiency Hypophosphatemia Anemia Hematologic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |
Gastroenteritis Anemia, Hypochromic Iron Metabolism Disorders Metabolic Diseases Phosphorus Metabolism Disorders Iron isomaltoside 1000 Hematinics |